TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MAPS (Men After Prostate Surgery) : Conservative Treatment for Men With Urinary Incontinence After Prostate Surgery; Multicentre Randomised Controlled Trial of Pelvic Floor Muscle Training and Biofeedback [MAPS]
Brief Summary: RATIONALE: Personalized training by a health professional may improve urinary incontinence. It is not yet known whether pelvic floor muscle training and biofeedback are more effective than standard therapy in improving urinary continence after radical prostatectomy or transurethral resection of the prostate.

PURPOSE: This randomized phase III trial is studying pelvic floor muscle training and biofeedback to see how well it works compared with standard therapy in men who have undergone radical prostatectomy or transurethral resection.


Options:
A: Arm Label: Kegel exercise education; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Extracorporeal biofeedback device; Type: EXPERIMENTAL; Interventions: Device: Extracorporeal biofeedback device (Any Kegel) | Intervention Type: DEVICE; Name: Extracorporeal biofeedback device (Any Kegel); Assigned to Arm(s): Extracorporeal biofeedback device
B: Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: biofeedback; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Arm Label: PILATES; Type: EXPERIMENTAL; Interventions: Other: Pilates | Arm Label: PFMT and AES; Type: ACTIVE_COMPARATOR; Interventions: Other: PFMT and AES | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Pilates; Assigned to Arm(s): PILATES | Intervention Type: OTHER; Name: PFMT and AES; Assigned to Arm(s): PFMT and AES | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Arm Label: BF+SUPPORT; Type: EXPERIMENTAL; Interventions: Behavioral: BF+SUPPORT | Arm Label: BF+PHONE; Type: EXPERIMENTAL; Interventions: Behavioral: BF+PHONE | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: BF+SUPPORT; Assigned to Arm(s): BF+SUPPORT | Intervention Type: BEHAVIORAL; Name: BF+PHONE; Assigned to Arm(s): BF+PHONE

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of a Smoking Quit Line in the Military
Brief Summary: Rates of cigarette smoking in the military are high. Tobacco telephone quit lines are telephone-based services that provide information and guidance to people who want to quit smoking. This study will evaluate the effectiveness of a tobacco quit line program, in addition to nicotine replacement patches, at helping people in the military quit smoking cigarettes.


Options:
A: Arm Label: Telephone counselling; Type: EXPERIMENTAL; Interventions: Device: Standard 15-minute telephone counselling, Device: Proactive telephone counselling | Arm Label: Proactive telephone counselling; Type: EXPERIMENTAL; Interventions: Device: Proactive telephone counselling | Arm Label: web-based smoking cessation programme; Type: EXPERIMENTAL; Interventions: Device: Interactive web-based smoking cessation programme | Arm Label: Self-help material; Type: ACTIVE_COMPARATOR; Interventions: Device: Self-help material | Intervention Type: DEVICE; Name: Standard 15-minute telephone counselling; Assigned to Arm(s): Telephone counselling | Intervention Type: DEVICE; Name: Proactive telephone counselling; Assigned to Arm(s): Proactive telephone counselling, Telephone counselling | Intervention Type: DEVICE; Name: Interactive web-based smoking cessation programme; Assigned to Arm(s): web-based smoking cessation programme | Intervention Type: DEVICE; Name: Self-help material; Assigned to Arm(s): Self-help material
B: Arm Label: Proactive group; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Behavioral: Tobacco Quit Line Program | Arm Label: Reactive group; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Behavioral: Tobacco Quit Line Program | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Proactive group, Reactive group | Intervention Type: BEHAVIORAL; Name: Tobacco Quit Line Program; Assigned to Arm(s): Proactive group, Reactive group
C: Intervention Type: BEHAVIORAL; Name: Coping-focused counseling telephone calls; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: QuitLink (office support system for quit line referral); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Novel Multimodal Intervention for Children With ADHD and Impaired Mood
Brief Summary: This study will evaluate the effectiveness of an integrative group psychosocial therapy combined with stimulant medication in treating children with attention deficit hyperactivity disorder plus impairments in mood.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Stimulant medication therapy, Behavioral: Community-based psychosocial treatment | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Group-based behavior therapy, Drug: Stimulant medication therapy | Intervention Type: BEHAVIORAL; Name: Group-based behavior therapy; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Stimulant medication therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Community-based psychosocial treatment; Assigned to Arm(s): 1
B: Arm Label: Combined therapy; Type: EXPERIMENTAL; Interventions: Drug: atomoxetine, Behavioral: Behavior Modification Therapy | Arm Label: Drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine | Intervention Type: DRUG; Name: atomoxetine; Assigned to Arm(s): Combined therapy, Drug therapy | Intervention Type: BEHAVIORAL; Name: Behavior Modification Therapy; Assigned to Arm(s): Combined therapy
C: Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A
D: Arm Label: Business as Usual (BAU); Type: OTHER; Interventions: Other: Business As Usual | Arm Label: Collaborative Life Skills Intervention (CLS); Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Life Skills Intervention (CLS) | Intervention Type: BEHAVIORAL; Name: Collaborative Life Skills Intervention (CLS); Assigned to Arm(s): Collaborative Life Skills Intervention (CLS) | Intervention Type: OTHER; Name: Business As Usual; Assigned to Arm(s): Business as Usual (BAU)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Laparoscopic Surgery and Pentoxifylline Therapy for Treatment of Endometriosis-Associated Infertility: A Preliminary Study
Brief Summary: To prove efficacy of an immunomodulator called pentoxifylline in the treatment of endometriosis in infertile patients undergoing laparoscopy surgery


Options:
A: Arm Label: Coenzyme Q10/CC group; Type: EXPERIMENTAL; Interventions: Drug: Coenzyme Q10, Drug: clomiphene citrate | Arm Label: CC alone group; Type: ACTIVE_COMPARATOR; Interventions: Drug: clomiphene citrate | Intervention Type: DRUG; Name: Coenzyme Q10; Assigned to Arm(s): Coenzyme Q10/CC group | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): CC alone group, Coenzyme Q10/CC group
B: Arm Label: I.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intrauterine insemination, Procedure: infertility | Arm Label: II.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intrauterine insemination, Procedure: infertility | Intervention Type: PROCEDURE; Name: intrauterine insemination; Assigned to Arm(s): I., II. | Intervention Type: PROCEDURE; Name: infertility; Assigned to Arm(s): I., II.
C: Arm Label: Berberine; Type: EXPERIMENTAL; Interventions: Drug: Berberine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Berberine; Assigned to Arm(s): Berberine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: pentoxifylline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pentoxifylline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Laparoscopic Surgery and Pentoxifylline Therapy for Treatment of Endometriosis-Associated Infertility: A Preliminary Study
Brief Summary: To prove efficacy of an immunomodulator called pentoxifylline in the treatment of endometriosis in infertile patients undergoing laparoscopy surgery


Options:
A: Arm Label: I.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intrauterine insemination, Procedure: infertility | Arm Label: II.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intrauterine insemination, Procedure: infertility | Intervention Type: PROCEDURE; Name: intrauterine insemination; Assigned to Arm(s): I., II. | Intervention Type: PROCEDURE; Name: infertility; Assigned to Arm(s): I., II.
B: Arm Label: N-Acetylcysteine; Type: EXPERIMENTAL; Interventions: Drug: N-Acetylcysteine | Arm Label: L-carnitine; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-carnitine | Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N-Acetylcysteine | Intervention Type: DRUG; Name: L-carnitine; Assigned to Arm(s): L-carnitine
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: pentoxifylline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pentoxifylline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Coenzyme Q10/CC group; Type: EXPERIMENTAL; Interventions: Drug: Coenzyme Q10, Drug: clomiphene citrate | Arm Label: CC alone group; Type: ACTIVE_COMPARATOR; Interventions: Drug: clomiphene citrate | Intervention Type: DRUG; Name: Coenzyme Q10; Assigned to Arm(s): Coenzyme Q10/CC group | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): CC alone group, Coenzyme Q10/CC group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus
Brief Summary: The purpose of this study is to evaluate the effects and safety of pioglitazone and berberine on the basis of lifestyle intervention to non-alcoholic fatty liver disease patients with impaired glucose regulation or type 2 diabetes mellitus.


Options:
A: Arm Label: treatment group; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E softgel | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vitamin E softgel; Assigned to Arm(s): treatment group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group
B: Arm Label: Sillymarin; Type: EXPERIMENTAL; Interventions: Drug: Sillymarin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sillymarin; Assigned to Arm(s): Sillymarin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention | Arm Label: Life style intervention, pioglitazone; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: pioglitazone | Arm Label: Life style intervention, berberine; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: berberine | Intervention Type: BEHAVIORAL; Name: Life style intervention; Assigned to Arm(s): Life style intervention, berberine, Life style intervention, pioglitazone, Lifestyle intervention | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Life style intervention, pioglitazone | Intervention Type: DRUG; Name: berberine; Assigned to Arm(s): Life style intervention, berberine
D: Arm Label: VSL#3 placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: VSL#3 placebo | Arm Label: VSL#3 active probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: VSL#3 active probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3 active probiotic; Assigned to Arm(s): VSL#3 active probiotic | Intervention Type: OTHER; Name: VSL#3 placebo; Assigned to Arm(s): VSL#3 placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus
Brief Summary: The purpose of this study is to evaluate the effects and safety of pioglitazone and berberine on the basis of lifestyle intervention to non-alcoholic fatty liver disease patients with impaired glucose regulation or type 2 diabetes mellitus.


Options:
A: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention | Arm Label: Life style intervention, pioglitazone; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: pioglitazone | Arm Label: Life style intervention, berberine; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: berberine | Intervention Type: BEHAVIORAL; Name: Life style intervention; Assigned to Arm(s): Life style intervention, berberine, Life style intervention, pioglitazone, Lifestyle intervention | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Life style intervention, pioglitazone | Intervention Type: DRUG; Name: berberine; Assigned to Arm(s): Life style intervention, berberine
B: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Polypill; Type: EXPERIMENTAL; Interventions: Drug: Polypill | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Polypill; Assigned to Arm(s): Polypill
D: Arm Label: Obeticholic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: obeticholic acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: obeticholic acid; Assigned to Arm(s): Obeticholic acid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Brief Summary: The purpose of this study is to see if adding the study drug, ziprasidone, to an antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD). We are studying the drug's effectiveness in treating depression, as well as its safety when it is added to another drug.

Hypothesis A: There will be a difference in the percentage of responders in the two treatment conditions during phase 2; response rates will be higher for the ziprasidone group.


Options:
A: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A
B: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ziprasidone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 1: venlafaxine plus aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: venlafaxine XR plus aripiprazole | Arm Label: 2: Placebo Comparator; Type: EXPERIMENTAL; Interventions: Drug: venlafaxine plus placebo | Intervention Type: DRUG; Name: venlafaxine XR plus aripiprazole; Assigned to Arm(s): 1: venlafaxine plus aripiprazole | Intervention Type: DRUG; Name: venlafaxine plus placebo; Assigned to Arm(s): 2: Placebo Comparator

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Narrow Band Versus Conventional Endoscopic Imaging for Screening Colonoscopy in a Private Practice Setting - A Large Prospective Randomized Trial
Brief Summary: Narrow Band Imaging (NBI) with high-definition (HDTV) visualization has been implemented into GI endoscopy with the purpose to better highlight endoluminal pathological structures by improving their contrast. Previous studies from referral centers could not show significant differences in terms of colonoscopic adenoma detection rate, but either very high adenoma rates or some numerical differences suggested that some benefit may exist which may become evident with average adenoma rates and/or large case numbers.

In a prospective randomized trial performed exclusively in a multicenter private practice setting involving 6 examiners with substantial life-time experience (\>10.000 colonoscopies) 1200 patients will undergo HDTV screening colonoscopy with either NBI or conventional imaging technique on instrument withdrawal. Primary outcome measure is the adenoma detection rate (ADR; i.e. number of adenomas per patient).


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Polp removal and identification, Procedure: ETMI colonoscope (ETMI scope is a FDA approved device) | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: colon polyp removal, Procedure: ETMI colonoscope (ETMI scope is a FDA approved device) | Intervention Type: PROCEDURE; Name: Polp removal and identification; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: colon polyp removal; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: ETMI colonoscope (ETMI scope is a FDA approved device); Assigned to Arm(s): 1, 2
B: Arm Label: colonoscopy; Type: EXPERIMENTAL; Interventions: Device: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test) | Intervention Type: DEVICE; Name: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test); Assigned to Arm(s): colonoscopy
C: Intervention Type: PROCEDURE; Name: Colonoscopy; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Narrow Band Versus Conventional Endoscopic Imaging for Screening Colonoscopy in a Private Practice Setting - A Large Prospective Randomized Trial
Brief Summary: Narrow Band Imaging (NBI) with high-definition (HDTV) visualization has been implemented into GI endoscopy with the purpose to better highlight endoluminal pathological structures by improving their contrast. Previous studies from referral centers could not show significant differences in terms of colonoscopic adenoma detection rate, but either very high adenoma rates or some numerical differences suggested that some benefit may exist which may become evident with average adenoma rates and/or large case numbers.

In a prospective randomized trial performed exclusively in a multicenter private practice setting involving 6 examiners with substantial life-time experience (\>10.000 colonoscopies) 1200 patients will undergo HDTV screening colonoscopy with either NBI or conventional imaging technique on instrument withdrawal. Primary outcome measure is the adenoma detection rate (ADR; i.e. number of adenomas per patient).


Options:
A: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
B: Arm Label: colonoscopy; Type: EXPERIMENTAL; Interventions: Device: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test) | Intervention Type: DEVICE; Name: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test); Assigned to Arm(s): colonoscopy
C: Arm Label: Narrow band imaging colonoscope; Type: EXPERIMENTAL; Interventions: Device: Narrow band imaging colonoscope | Arm Label: White Light; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Narrow band imaging colonoscope; Assigned to Arm(s): Narrow band imaging colonoscope
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: standard of care colonoscopy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: standard of care colonoscopy | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Procedure: colonoscopy | Intervention Type: PROCEDURE; Name: standard of care colonoscopy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: colonoscopy; Assigned to Arm(s): 3 | Intervention Type: PROCEDURE; Name: standard of care colonoscopy; Assigned to Arm(s): 2

Answer: B